MetaCap

Aclaris Therapeutics (ACRS) vs Design Therapeutics (DSGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aclaris Therapeutics (ACRS) has outperformed Design Therapeutics (DSGN) over the past year, gaining 37.1% versus a gain of 8.0%. Over five years, DSGN leads with a -49.3% price change compared with -72.7% for ACRS. Design Therapeutics is the larger company by market cap ($577.6 million vs $545.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRS+37.05%DSGN+8.02%
+168%+80%-8%
Nov 21, 20251 yearNov 20, 2026
ACRS-75.05%DSGN-56.02%
+40%-30%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRS versus DSGN key metrics
MetricACRSDSGN
Share price$3.44$9.02
Market cap$545.63M$577.61M
1-day change-1.71%-3.22%
YTD return+14.29%-3.84%
1-year return+37.05%+8.02%
5-year return-72.74%-49.27%
EPS (TTM)$-0.59$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.83M$0
Revenue growth (YoY)-58.19%—
Net income (latest FY)$-64.92M$-69.79M
Gross margin73.28%—
Operating margin-975.91%—
Net margin-829.58%—
52-week high$6.60$17.25
52-week low$2.46$8.21
Distance from 52-week high-47.88%-47.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+205.23%+139.14%
Average volume3.07M554.69K
Shares outstanding158.61M64.04M
Employees6960
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACRS has outperformed DSGN by 29.0 percentage points over the past year.

About Aclaris Therapeutics

ACRS stock →

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Design Therapeutics

DSGN stock →

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

ACRS vs DSGN FAQ

Which is bigger, Aclaris Therapeutics or Design Therapeutics?

Design Therapeutics (DSGN) is larger, with a market capitalization of $577.61M compared with $545.63M for Aclaris Therapeutics (ACRS).

Which stock has performed better over the past year, ACRS or DSGN?

ACRS returned +37.05% over the past 12 months, compared with +8.02% for DSGN (price return, excluding dividends). Past performance does not predict future results.

Are Aclaris Therapeutics and Design Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons